At the moment, clinical studies are primarily investigating the anti-SARS-CoV-2 activity of TMPRSS2 inhibitors, with a focus on symptomatic and/or hospitalized COVID-19 patients. This evidence concerns the gene TMPRSS2 and COVID-19.